205 related articles for article (PubMed ID: 31763975)
21. Identification, substrate specificity, and inhibition of the Streptococcus pneumoniae beta-ketoacyl-acyl carrier protein synthase III (FabH).
Khandekar SS; Gentry DR; Van Aller GS; Warren P; Xiang H; Silverman C; Doyle ML; Chambers PA; Konstantinidis AK; Brandt M; Daines RA; Lonsdale JT
J Biol Chem; 2001 Aug; 276(32):30024-30. PubMed ID: 11375394
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of 2-styryl of 5-Nitroimidazole derivatives and antimicrobial activities as FabH inhibitors.
Duan YT; Wang ZC; Sang YL; Tao XX; Teraiya SB; Wang PF; Wen Q; Zhou XJ; Ding L; Yang YH; Zhu HL
Eur J Med Chem; 2014 Apr; 76():387-96. PubMed ID: 24594526
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and antimicrobial activities of oximes derived from O-benzylhydroxylamine as FabH inhibitors.
Luo Y; Zhang LR; Hu Y; Zhang S; Fu J; Wang XM; Zhu HL
ChemMedChem; 2012 Sep; 7(9):1587-93. PubMed ID: 22811397
[TBL] [Abstract][Full Text] [Related]
24. Structural and dynamical aspects of Streptococcus gordonii FabH through molecular docking and MD simulations.
Shamim A; Abbasi SW; Azam SS
J Mol Graph Model; 2015 Jul; 60():180-96. PubMed ID: 26059477
[TBL] [Abstract][Full Text] [Related]
25. Novel FabH inhibitors: an updated article literature review (July 2012 to June 2013).
Song H; Ao GZ; Li HQ
Expert Opin Ther Pat; 2014 Jan; 24(1):19-27. PubMed ID: 24083428
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure and substrate specificity of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus.
Qiu X; Choudhry AE; Janson CA; Grooms M; Daines RA; Lonsdale JT; Khandekar SS
Protein Sci; 2005 Aug; 14(8):2087-94. PubMed ID: 15987898
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of metronidazole-thiazole derivatives as antibacterial inhibitors.
Qin YJ; Wang PF; Makawana JA; Wang ZC; Wang ZN; Yan-Gu ; Jiang AQ; Zhu HL
Bioorg Med Chem Lett; 2014 Nov; 24(22):5279-83. PubMed ID: 25587588
[TBL] [Abstract][Full Text] [Related]
28. Molecular dynamics and docking simulations as a proof of high flexibility in E. coli FabH and its relevance for accurate inhibitor modeling.
Pérez-Castillo Y; Froeyen M; Cabrera-Pérez MA; Nowé A
J Comput Aided Mol Des; 2011 Apr; 25(4):371-93. PubMed ID: 21516317
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.
Zheng Z; Parsons JB; Tangallapally R; Zhang W; Rock CO; Lee RE
Bioorg Med Chem Lett; 2014 Jun; 24(11):2585-8. PubMed ID: 24755430
[TBL] [Abstract][Full Text] [Related]
30. Purification, characterization, and identification of novel inhibitors of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus.
He X; Reynolds KA
Antimicrob Agents Chemother; 2002 May; 46(5):1310-8. PubMed ID: 11959561
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Novel Antibiotics as Covalent Inhibitors of Fatty Acid Synthesis.
Wang J; Ye X; Yang X; Cai Y; Wang S; Tang J; Sachdeva M; Qian Y; Hu W; Leeds JA; Yuan Y
ACS Chem Biol; 2020 Jul; 15(7):1826-1834. PubMed ID: 32568510
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel oxoindolin derivatives as atypical dual inhibitors for DNA Gyrase and FabH.
Yang YS; Su MM; Xu JF; Liu QX; Bai LF; Hu XW; Zhu HL
Bioorg Chem; 2019 Dec; 93():103309. PubMed ID: 31585266
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of thiazolidine-2-one 1,1-dioxide as inhibitors of Escherichia coli beta-ketoacyl-ACP-synthase III (FabH).
Alhamadsheh MM; Waters NC; Huddler DP; Kreishman-Deitrick M; Florova G; Reynolds KA
Bioorg Med Chem Lett; 2007 Feb; 17(4):879-83. PubMed ID: 17189694
[TBL] [Abstract][Full Text] [Related]
34. Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping.
McKinney DC; Eyermann CJ; Gu RF; Hu J; Kazmirski SL; Lahiri SD; McKenzie AR; Shapiro AB; Breault G
ACS Infect Dis; 2016 Jul; 2(7):456-64. PubMed ID: 27626097
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and antibacterial activity studies of thiazole derivatives as potent ecKAS III inhibitors.
Cheng K; Xue JY; Zhu HL
Bioorg Med Chem Lett; 2013 Jul; 23(14):4235-8. PubMed ID: 23731945
[TBL] [Abstract][Full Text] [Related]
36. Advances in the research of β-ketoacyl-ACP synthase III (FabH) inhibitors.
Zhang HJ; Li ZL; Zhu HL
Curr Med Chem; 2012; 19(8):1225-37. PubMed ID: 22257054
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis and Antibacterial Activities of Novel Amide Derivatives Bearing Dioxygenated Rings as Potential β-Ketoacyl-acyl Carrier Protein Synthase III (FabH) Inhibitors.
Zhou Y; Liang YQ; Wang XY; Chang HY; Hu SP; Sun J
Chem Pharm Bull (Tokyo); 2022; 70(8):544-549. PubMed ID: 35908920
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis and Molecular Docking of 1,3,4-Oxadiazole-2(3H)-thione Derivatives Containing 1,4-Benzodioxane Skeleton as Potential FabH Inhibitors.
Sun J; Zhang CP; Chen CH; Guo XM; Liu CS; Zhou Y; Hu FL
Chem Biodivers; 2023 Feb; 20(2):e202201060. PubMed ID: 36579401
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of chrysin derivatives as potential FabH inhibitors.
Li HX; Wang ZC; Qian YM; Yan XQ; Lu YD; Zhu HL
Chem Biol Drug Des; 2017 Jan; 89(1):136-140. PubMed ID: 27860280
[TBL] [Abstract][Full Text] [Related]
40. Study of Schiff-Base-Derived with Dioxygenated Rings and Nitrogen Heterocycle as Potential β-Ketoacyl-acyl Carrier Protein Synthase III (FabH) Inhibitors.
Zhou Y; Yang YS; Song XD; Lu L; Zhu HL
Chem Pharm Bull (Tokyo); 2017; 65(2):178-185. PubMed ID: 28154310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
